| 08: 10: Racial Patterns of Thyroid Cancer Incidence in the US LPA Burgess, RP Zitsch, LGT Morris, A Sikora, D Jethanamest, ... Otolaryngology--Head and Neck Surgery 137 (2_suppl), P49-P49, 2007 | | 2007 |
| 11: 06: Malpractice Litigation after Tonsillectomy: 156 Cases LPA Burgess, JL Levine, LGT Morris, SD Reitzen, SM Lieberman, ... Otolaryngology--Head and Neck Surgery 137 (2_suppl), P105-P106, 2007 | | 2007 |
| 18 Surgical Management of Anaplastic Thyroid Cancer BR Untch, LGT Morris Thyroid and Parathyroid Diseases: Medical and Surgical Management, 149, 2016 | | 2016 |
| 2874 Impact of white adipose tissue inflammation on survival in patients with squamous cell carcinoma of the oral tongue N Iyengar, R Ghossein, A Kochhar, L Morris, X Zhou, P Morris, M Awad, ... European Journal of Cancer 3 (51), S581, 2015 | | 2015 |
| 343 Defining and therapeutically targeting a fusion-derived public neoantigen in desmoplastic small round cell tumor using T-cell receptor gene therapy L Banks, H Arkin, SS Chandran, E Slotkin, N Shukla, L Morris, A Kung, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 3p arm loss and survival in head and neck cancer: an analysis of TCGA dataset HAJ Kim, MH Shaikh, M Lee, PYF Zeng, A Sorgini, T Akintola, X Deng, ... Cancers 13 (21), 5313, 2021 | 3 | 2021 |
| 503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma A Afeyan, G Oliveira, AM Egloff, Z Zeng, R Chernock, L Zhou, C Messier, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| 526 Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic features T Chang, Y Cao, H Sfreddo, SR Dhruba, SH Lee, C Valero, SK Yoo, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 82nd Annual Meeting of the American Thyroid AssociationMEETING ABSTRACTS & PROGRAM N Schoenmakers, B Bak, Y Sun, PVAN Trotsenburg, W Oostdijk, P Voshol, ... Thyroid (New York, NY) 22 (S1), A-1-A-124, 2012 | | 2012 |
| A nomogram to predict loco-regional control after re-irradiation for head and neck cancer N Riaz, JC Hong, EJ Sherman, L Morris, M Fury, I Ganly, TJC Wang, ... Radiotherapy and Oncology 111 (3), 382-387, 2014 | 83 | 2014 |
| A novel tumor: specimen index for assessing adequacy of resection in early stage oral tongue cancer PH Montero, FL Palmer, AG Shuman, PD Patel, JO Boyle, DH Kraus, ... Oral oncology 50 (3), 213-220, 2014 | 12 | 2014 |
| A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx … N Riaz, EJ Sherman, N Katabi, JE Leeman, DS Higginson, J Boyle, ... Journal of Clinical Oncology 35 (15_suppl), 6076-6076, 2017 | 8 | 2017 |
| A personalized approach using hypoxia resolution to guide curative-intent radiation therapy dose-reduction to 30 Gy: a novel de-escalation paradigm for HPV-associated … N Riaz, E Sherman, N Katabi, JE Leeman, DS Higginson, JO Boyle, ... International Journal of Radiation Oncology, Biology, Physics 99 (2), S136, 2017 | 5 | 2017 |
| A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy E Tolosa, I Litvan, GU Höglinger, D Burn, A Lees, MV Andrés, ... Movement Disorders 29 (4), 470-478, 2014 | 296 | 2014 |
| A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma AL Ho, L Dunn, EJ Sherman, MG Fury, SS Baxi, R Chandramohan, ... Annals of Oncology 27 (10), 1902-1908, 2016 | 83 | 2016 |
| A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). V Tchekmedyian, EJ Sherman, L Dunn, JV Fetten, LS Michel, A Kriplani, ... Journal of Clinical Oncology 37 (15_suppl), 6084-6084, 2019 | 36 | 2019 |
| A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs). B Burman, EJ Sherman, L Dunn, JV Fetten, LS Michel, LGT Morris, ... Journal of Clinical Oncology 39 (15_suppl), 6002-6002, 2021 | 16 | 2021 |
| A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-COX Inhibitor, in Oral Premalignant Lesions AR Shaha, B Singh, RJ Wong, L Morris, CS Moskowitz, I Orlow, N Katabi, ... IRB 4 (099A), 18, 0 | | |
| A pilot study of neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab in patients with resectable, locally advanced head and neck squamous cell carcinoma … L Dunn, EJ Sherman, AL Ho, I Ganly, N Riaz, L Morris, KW Hung, ... Journal of Clinical Oncology 40 (16_suppl), TPS6109-TPS6109, 2022 | 1 | 2022 |
| Abstract IA11: Interactions between the genome and immune microenvironment in head and neck cancer LGT Morris Clinical Cancer Research 23 (23_Supplement), IA11-IA11, 2017 | | 2017 |
